Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Lilly Japan Sales Up 7% in 2017, Upbeat Biz Fueled by Global Simultaneous Development
March 23, 2018
- Eldecalcitol NDA Accepted in China: Chugai
March 23, 2018
- J-TEC’s Cell Sheet JACE Filed for Epidermolysis Bullosa
March 23, 2018
- EA Pharma, Irish Cosmo Technologies Hook Up on Colonoscopy Products
March 23, 2018
- Single Generic Pricing Rule Will Accelerate Unreasonable Price Raises: Sawai Chief
March 22, 2018
- Takeda Global Headquarters Completed
March 22, 2018
- Mircera 12.5μg Version Approved in Japan: Chugai
March 22, 2018
- Life Science Institute to Launch Cell Processing Center for Muse Cells, Aiming to Commence Operations in Jan. 2019
March 22, 2018
- Toho Forms Capital Alliance with Tokyo Upstart HekaBio
March 20, 2018
- Hitachi Chemical Wins Clinical Regenerative Medicine Manufacturing Deal from Daiichi Sankyo
March 20, 2018
- Opdivo Picks Up HCC Nod in Taiwan
March 20, 2018
- Top Court Slaps Down Debiopharm’s Appeal over Elplat Patent
March 20, 2018
- Xtandi Gets FDA Priority Review Status for Add’l CRPC Indication
March 20, 2018
- IBL, Astellas Wind Up Human Fibrinogen Collaboration
March 20, 2018
- Bioverativ Earns Approval for 4,000 IU Version for Hemophilia B Treatment Alprolix
March 20, 2018
- Toho to Thoroughly Implement Drug Distribution GL, Focus on Cost-Cutting in Response to Impact of Drug Pricing Reform: Pres.
March 20, 2018
- Takeda Bolstering Pitch for Inisync, Takecab in December: Anterio Ranking
March 19, 2018
- Ethical Drug Sales Up 3.6% in January on AbbVie Hep C Drug, Seasonal Factors
March 19, 2018
- EMA Accepts Filing for Xtandi’s CRPC Label Expansion
March 19, 2018
- Shionogi Nabs Rights to Osaka Upstart’s Tissue Regeneration-Inducing Peptide
March 16, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…